{"schema_version":"secwatch.filing_event.v1","accession":"0001601830-25-000126","form_type":"8-K","ticker":"RXRX","cik":"0001601830","company_name":"RECURSION PHARMACEUTICALS, INC.","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.465410+00:00","generated_at":"2026-05-17T20:42:48.998037+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"low","headline":"Recursion Q2 2025: $7M Sanofi milestone; REC-1245 and REC-617 trial updates","bullets":["Announced $7 million milestone from Sanofi partnership for partnered discovery program.","REC-1245 (RBM39) DAHLIA Phase 1/2 trial enrolling patients with tumors exhibiting replication stress and DDR vulnerabilities.","REC-617 (CDK7 inhibitor) combination cohort to target platinum-resistant ovarian cancer using multi-omic and causal AI.","Co-founder and CEO Chris Gibson highlighted platform advancements including Boltz-2 for ligand design.","Exhibit text truncated; specific Q2 revenue, EPS, and cash position figures were not provided in the available excerpt."],"urls":{"canonical":"https://secwatch.observer/filing/0001601830-25-000126","json":"https://secwatch.observer/filing/0001601830-25-000126.json","markdown":"https://secwatch.observer/filing/0001601830-25-000126.md","text":"https://secwatch.observer/filing/0001601830-25-000126.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601830/000160183025000126/0001601830-25-000126-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601830/000160183025000126/rxrx-20250805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:42:48.998037+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}